Advertisement

Citations to this article

Abstract

Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas. pSTAT3 is found in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR. Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, whereas a pan-JAK inhibitor (P6) blocked activation of STAT3 and inhibited tumorigenesis. Cell lines expressing these persistently activated mutant EGFRs also produced high IL-6 levels, and blockade of the IL-6/gp130/JAK pathway led to a decrease in pSTAT3 levels. In addition, reduction of IL-6 levels by RNA interference led to a decrease in tumorigenesis. Introduction of persistently activated EGFR into immortalized breast epithelial cells led to tumorigenesis, IL-6 expression, and STAT3 activation, all of which could be inhibited with P6 or gp130 blockade. Furthermore, inhibition of EGFR activity in multiple cell lines partially blocked transcription of IL-6 and concurrently decreased production and release of IL-6. Finally, immunohistochemical analysis revealed a positive correlation between pSTAT3 and IL-6 positivity in primary lung adenocarcinomas. Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by means of IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment.

Authors

Sizhi Paul Gao ... Bayard Clarkson, Jacqueline F. Bromberg

×

Total citations by year in Crossref

Year: 2015 2014 2013 2012 2011 2010 2009 2008 Total
Citations: 10 25 14 17 11 12 15 5 109
Citation information

Citations to this article in Crossref (109)

Title and authors Publication Year
Comparisons of the Efficacy of a Jak1/2 Inhibitor (AZD1480) with a VEGF Signaling Inhibitor (Cediranib) and Sham Treatments in Mouse Tumors Using DCE-MRI, DW-MRI, and Histology
ME Loveless, D Lawson, M Collins, MV Nadella, C Reimer, D Huszar, J Halliday, JC Waterton, JC Gore, TE Yankeelov
Neoplasia (New York, N.Y.) 2012
Radioimmunoimaging with Mixed Monoclonal Antibodies of Nude Mice Bearing Human Lung Adenocarcinoma Xenografts
D Duan, SL Li, YQ Zhu, T Zhang, CM Lei, XH Cheng
Asian Pacific Journal of Cancer Prevention 2012
STAT3 as a therapeutic target for Epstein-Barr virus (EBV) – associated nasopharyngeal carcinoma
Y Ho, SW Tsao, M Zeng, VW Lui
Cancer Letters 2012
Overexpression of signal transducer and activator of transcription (STAT-3 and STAT-5) transcription factors and alteration of suppressor of cytokine signaling (SOCS-1) protein in prostate cancer
N Singh, S Hussain, M Bharadwaj, N Kakkar, SK Singh, RC Sobti
Journal of Receptors and Signal Transduction 2012
A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk
J Chen, RY Liu, L Yang, J Zhao, X Zhao, D Lu, N Yi, B Han, XF Chen, K Zhang, J He, Z Lei, Y Zhou, B Pasche, X Li, HT Zhang
Journal of Cancer Research and Clinical Oncology 2012
EGFR inhibitor BIBU induces apoptosis and defective autophagy in glioma cells
R Ghildiyal, D Dixit, E Sen
Molecular Carcinogenesis 2012
Stat3: Linking inflammation to (gastrointestinal) tumourigenesis
M Ernst, TL Putoczki
Clinical and Experimental Pharmacology and Physiology 2012
Acetylation modulates the STAT signaling code
M Wieczorek, T Ginter, P Brand, T Heinzel, OH Krämer
Cytokine & Growth Factor Reviews 2012
Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway
HS Hsu, JH Lin, TW Hsu, K Su, CW Wang, KY Yang, SH Chiou, SC Hung
Lung Cancer 2012
The role of pseudokinases in cancer
H Zhang, A Photiou, G Arnhild, J Stebbing, G Giamas
Cellular Signalling 2012
Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling
X Jin, SH Kim, HM Jeon, S Beck, YW Sohn, J Yin, JK Kim, YC Lim, JH Lee, SH Kim, SH Kang, X Pian, MS Song, JB Park, YS Chae, YG Chung, SH Lee, YJ Choi, DH Nam, YK Choi, H Kim
Brain 2012
p14ARF inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway
P Ozenne, D Dayde, E Brambilla, B Eymin, S Gazzeri
Oncogene 2012
Interleukin-6 signaling pathway in targeted therapy for cancer
Y Guo, F Xu, TJ Lu, Z Duan, Z Zhang
Cancer Treatment Reviews 2012
Involvement of STAT3, NF-κB and associated downstream molecules before and after the onset of urethane induced lung tumors in mouse
M Pandey, KP Gupta
Environmental Toxicology and Pharmacology 2012
DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors
UJ Yun, SE Park, YS Jo, J Kim, DY Shin
Cancer Letters 2012
ER stress-induced inflammation: does it aid or impede disease progression?
AD Garg, A Kaczmarek, O Krysko, P Vandenabeele, DV Krysko, P Agostinis
Trends in Molecular Medicine 2012
Correlation of Activated STAT3 Expression with Clinicopathologic Features in Lung Adenocarcinoma and Squamous Cell Carcinoma
R Jiang, Z Jin, Z Liu, L Sun, L Wang, K Li
Molecular diagnosis & therapy 2011
Inflamm-aging of the stem cell niche: Breast cancer as a paradigmatic example : Breakdown of the multi-shell cytokine network fuels cancer in aged people
M Bonafè, G Storci, C Franceschi
BioEssays 2011
Notch-Induced hIL-6 Production Facilitates the Maintenance of Self-Renewal of hCD34+ Cord Blood Cells Through the Activation of Jak-PI3K-STAT3 Pathway
B Choi, E Chun, SY Kim, M Kim, KY Lee, SJ Kim
The American Journal of Pathology 2011
Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer
D Drygin, CB Ho, M Omori, J Bliesath, C Proffitt, R Rice, A Siddiqui-Jain, S O’Brien, C Padgett, JK Lim, K Anderes, WG Rice, D Ryckman
Biochemical and Biophysical Research Communications 2011
Rapid Symptomatic Improvement in Gefitinib-Treated Patients with EGFR-Mutated Lung Cancer: Possible Role of Downregulation of Inflammatory Molecules?
EN Suspitsin, EV Levchenko, FV Moiseyenko, AO Ivantsov, SA Radzhabova, DE Matsko, VM Moiseyenko, EN Imyanitov
Onkologie 2011
Mathematical model of the role of intercellular signalling in intercellular cooperation during tumorigenesis
S Ghosh, S Elankumaran, IK Puri
Cell Proliferation 2011
Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs
IK Guttilla, KN Phoenix, X Hong, JS Tirnauer, KP Claffey, BA White
Breast Cancer Research and Treatment 2011
The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
A Chalaris, C Garbers, B Rabe, S Rose-John, J Scheller
European Journal of Cell Biology 2011
CK2 Inhibitors Enhance the Radiosensitivity of Human Non-Small Cell Lung Cancer Cells Through Inhibition of Stat3 Activation
YC Lin, MS Hung, CK Lin, JM Li, KD Lee, YC Li, MF Chen, JK Chen, CT Yang
Cancer Biotherapy & Radiopharmaceuticals 2011

Advertisement
Advertisement